Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.

You may also be interested in...



ArQule Gets Early-Stage Cancer Program Back From Daiichi

The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.

ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo

Two deals bring the biotech $75 million upfront, plus research and clinical development funding.

ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo

Two deals bring the biotech $75 million upfront, plus research and clinical development funding.

Related Content

Topics

UsernamePublicRestriction

Register

PS065963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel